Editorial | Hong Kong is right to hold the line against US vaccine scepticism
As Hong Kong steps up its fight against viral hepatitis, health authorities are right not to follow a US policy shift on the hepatitis B vaccine

For decades, universal vaccination of infants has been a triumph of public health. Since Hong Kong introduced it in 1988, the practice has slashed infection rates and chronic liver disease cases. However, progress can be lost quickly in a densely populated city. A 2020-22 government survey showed 410,000 people in the city were living with hepatitis B. The virus is still the leading cause of liver cancer. More work is needed.
Medical decisions are intensely personal, and some patients have underlying health issues or allergies to consider. However, choices should be made in consultation with health professionals rather than based on anxiety, trends or self-guided online research.
As the authorities expand the fight against hepatitis B, it is good they are holding the line against overseas policy shifts. Awareness and smart health programmes can help inoculate the city against scepticism spreading from abroad.
